secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-10-06T12:00:20+00:00
Accession:  0001178913-26-004720
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Entera Bio adds ex-Gilead EVP Laura Hamill to board; Yonatan Malca exits after 16 years
--------------------------------------------------------------------------------

- Laura Hamill, 62, appointed Class I director effective December 1, 2026; also joins the audit and corporate governance/nomination committees.
- Hamill was EVP Worldwide Commercial Operations at Gilead Sciences, leading ~2,500 employees and $22B in annual revenue; spent nearly two decades at Amgen.
- She succeeds Yonatan Malca, who steps down December 1, 2026 after 16 years of service; company says departure is not due to any disagreement.
- CEO Miranda Toledano cites Hamill's experience for late-stage execution and commercial preparedness for EB613 in osteoporosis and the oral peptide pipeline.
- Hamill currently sits on boards of Jazz Pharmaceuticals (JAZZ), BB Biotech AG and Fate Therapeutics (FATE); compensation is standard non-employee director terms under the 2018 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/0001178913-26-004720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/zk2636199.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer